# Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France

> **NCT05359276** · — · COMPLETED · sponsor: **Sanofi** · enrollment: 40 (actual)

## Conditions studied

- Acid Sphingomyelinase Deficiency (ASMD)

## Interventions

- **DRUG:** Olipudase alfa

## Key facts

- **NCT ID:** NCT05359276
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359276, "Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05359276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*